Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioVie ( (BIVI) ) just unveiled an update.
On November 10, 2025, BioVie Inc. held its annual meeting of stockholders, where several key proposals were considered. Stockholders elected the company’s nominees for director for one-year terms, ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance.
The most recent analyst rating on (BIVI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.
Spark’s Take on BIVI Stock
According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.
BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.
To see Spark’s full report on BIVI stock, click here.
More about BioVie
Average Trading Volume: 216,774
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.75M
For detailed information about BIVI stock, go to TipRanks’ Stock Analysis page.